The FDA has granted 510(k) clearance to NeuroXT's NEXT-Cue, a Class II software-as-a-medical-device that combines brain MRI, demographic data, and cognitive testing to estimate whether a patient with mild cognitive impairment will progress to Alzheimer's dementia within five years. The clearance extends risk stratification in cognitive decline from single-modality imaging toward integrated, algorithmically derived prediction. For longevity practice, it compresses the window between the first measurable signal of cognitive change and the decision to intervene.
Key Points
- FDA clears AI tool predicting five-year Alzheimer's progression in mild cognitive impairment
- Software integrates brain MRI, demographics, and cognitive assessment data
- Korean regulatory submission underway, with commercialization planned next year
Longevity Analysis
Mild cognitive impairment is a heterogeneous state — some patients remain stable for a decade, others convert within two years — and that ambiguity has historically delayed meaningful action. Converting diffuse structural and cognitive signals into a quantified five-year trajectory gives clinicians a defensible basis for intensifying the interventions that actually influence neural resilience: cerebral perfusion, sleep-dependent clearance of metabolic waste, metabolic and hormonal control, and sustained physical and cognitive load. The value lies less in the prediction itself than in what it makes possible — earlier, better-targeted, and more consistently executed protection of the brain's capacity to repair.
Original published by LT Wire.